TrialBlood2018

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Ann S LaCasce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.